Medical devices, healthcare technology and the business of care
510(k) clearance · K263073

Fast Absorbing PGLA

Riverpoint Medical, LLC · Decision date Sep 29, 2026

MEDTECHLEDGER EXPLANATIONK263073

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for K263073, Fast Absorbing PGLA, on September 29, 2026, with the submission received September 1, 2026. The applicant is Riverpoint Medical, LLC of Portland, Oregon; the device falls under 21 CFR 878.4493, product code GAM, in the General and Plastic Surgery panel. The public record lists the review as a Special 510(k), not reviewed by a third party, and not a combination product. SE denotes clearance to market under general controls, not premarket approval.

The device is a braided, coated synthetic absorbable suture of polyglycolic-lactic acid with a poly(glycolide-co-L-lactide) and calcium stearate coating, supplied sterile for single use, with or without a needle. The summary identifies K120556 (Vilet Quick) as the predicate and states the only difference is labeling that adds a contraindication for ligation, ophthalmic, cardiovascular and neurological procedures. The indications enclosure limits use to superficial soft tissue approximation of skin and mucosa needing short-term wound support. The record does not disclose clinical outcome data or the basis for the 7-10 day support period.

Regulatory pathway
510(k) premarket notification
Clinical specialty
General, Plastic Surgery
Decision date
Sep 29, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K263073
Regulatory pathway
510(k) premarket notification
Product code
GAM
Decision code
SESE
Decision date
Sep 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Suture, Absorbable, Synthetic, Polyglycolic Acid.

Product code
GAM
FDA device class
2

FDA decision timeline

  1. K263073 received

    Application receipt date recorded by FDA.

  2. K263073 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Riverpoint Medical, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Portland, OR

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records